Speedy review for PharmaMar's Zepsyre

17 February 2020

The US Food and Drug Administration has awarded Priority Review to a submission from Spanish drugmaker PharmaMar (MC: PHM) and Jazz Pharmaceuticals (Nasdaq: JAZZ) for lurbinectedin.

Towards the end of 2019, PharmaMar agreed a deal with Ireland-incorporated Jazz Pharma for lurbinectedin in the USA.

That agreement, worth up to a billion dollars for PharmaMar, was reached shortly after the firm submitted its application to the US regulator, for the treatment of people with relapsed small-cell lung cancer (SCLC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK